Send the following on WhatsApp
Continue to ChatMolecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma - https://avesis.istanbul.edu.tr/yayin/2049990f-daa5-40d7-a024-1f3c5cf3e20a/molecular-determinants-of-clinical-outcomes-with-pembrolizumab-versus-paclitaxel-in-a-randomized-open-label-phase-iii-trial-in-patients-with-gastroesophageal-adenocarcinoma